Fundraising FoxRegenerative Medical Solutions
Chicago, US · Founded 2011 · Delaware corporation
Find your way into Regenerative Medical Solutions
Sign up to see every warm intro you have to Regenerative Medical Solutions
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Regenerative Medical Solutions team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
RMS develops stem cell therapies to regenerate insulin-producing pancreatic beta cells as a potential cure for Type 1 and Type 2 diabetes. The company uses induced pluripotent stem cell (iPSC) technology to create scalable, non-embryonic solutions that aim to restore natural insulin function.
Founders & leadership
Regenerative Medical Solutions was founded in 2011 by Jon S. Odorico, MD, FACS and Dr. Jon Odorico.
JS
Jon S. Odorico, MD, FACSCo-founder
DJ
Dr. Jon OdoricoScientific Founder
GT
Guy TagliaviaChief Operating OfficerGuy Tagliavia is Chief Operating Officer of Regenerative Medical Solutions and heads GT Advisory Group, LLC, a business advisory firm. He has over 35 years of experience in leadership roles across financial services, biomedical research, and operations, with particular expertise in strategic business development, product-market expansion, and regenerative medicine including stem cell and cell differentiation technologies.
Board
GG
Gary GormanFounding Partner
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 4 rounds · 2014–2023
▶$5MraisedAug 2023 · 2 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony D. KoltonExecutive Officer, Director
- Amount sold
- $5M
- Minimum investment
- $25K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$181KraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$181KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony D. KoltonExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $181K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$375KraisedNov 2014 · 1 investors · BiotechnologyRule 506(b)
▶$375KraisedNov 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas JoyceExecutive Officer
- Anthony D. KoltonExecutive Officer, Director
- Guy TagliaviaExecutive Officer
- Offering amount
- $3M
- Amount sold
- $375K
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$595KraisedJul 2014 · 9 investors · BiotechnologyRule 506(b)
▶$595KraisedJul 2014 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony D. KoltonExecutive Officer, Director
- Guy TagliaviaExecutive Officer
- Gary GormanDirector
- Jon S. Odorico, MD, FACSDirector
- Thomas P. JoyceExecutive Officer
- Offering amount
- $1M
- Amount sold
- $595K
- Minimum investment
- $25K
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
DiabetesA nonprofit organization that provides educational resources and information about prediabetes, including prevention strategies and lifestyle management for Americans at risk of developing type 2 diabetes.
IntechopenIntechOpen is an open access publisher of books and open science journals covering science, technology, and medicine, serving academics and researchers across interdisciplinary fields. It also operates a book series model with editorial-board-led topics and a custom manuscript submission and peer review platform.
Companies working in the same space as Regenerative Medical Solutions.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $275K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $259.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $217.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $222K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Regenerative Medical Solutions do?
- RMS develops stem cell therapies to regenerate insulin-producing pancreatic beta cells as a potential cure for Type 1 and Type 2 diabetes. The company uses induced pluripotent stem cell (iPSC) technology to create scalable, non-embryonic solutions that aim to restore natural insulin function.
- Who founded Regenerative Medical Solutions?
- Regenerative Medical Solutions was founded by Jon S. Odorico, MD, FACS, Dr. Jon Odorico in 2011.
- How much funding has Regenerative Medical Solutions raised?
- Regenerative Medical Solutions has disclosed $6.2M raised across 4 rounds.
- Where is Regenerative Medical Solutions headquartered?
- Regenerative Medical Solutions is headquartered in Chicago, US.